Tag: Johnson & Johnson

Biosense Webster announces first patients enrolled in post-market approval study for...

Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External...

New data demonstrates >90% year 1 success rate for radiofrequency ablation...

Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...